Resources
AI in pharma is an architecture decision.
Most companies are arguing about model selection. The ones that win are quietly building the unglamorous foundations underneath.
Pharma does not have an AI problem. It has a building problem. Every executive has heard the AI pitch a hundred times. Every consultancy has a deck. The companies that will deploy AI successfully in regulated industries are not the ones with the best strategy decks. They are the ones who built the architecture three years before anyone noticed it mattered.
That architecture is not exciting. It is ontology layers, governance scaffolding, MLR workflow design, audit trails, and human in the loop accountability. Boring infrastructure that does not photograph well in an annual report. Foundational work that makes the difference between an AI deployment that ships and one that quietly stalls in pilot for the third year running.
This collection covers how to think about AI in pharma. What to fund. What to skip. Why the deployment model matters more than the model selection. Why human approval is not a feature in pharma AI, it is the only model that survives a regulatory audit. If you are a pharma operator trying to make AI decisions that compound, the writing here is meant for you.
Key Insights
What the writing is showing.
Pharma does not have an AI problem. It has a building problem.
Frontier AI models become commodities every quarter. Architecture is the durable investment.
Gartner projects 40 percent of agentic AI initiatives will be cancelled by 2027 because organizations skip foundation work.
The FDA issued 40 untitled letters in a single day in September 2025. AI deployments without audit trails are next.
Companies that built ontology and governance in 2023 will look like they suddenly pulled ahead in 2027.
Read Deeper
Articles in this collection.
Pharma, AI
The Audit Trail Problem: Why Pharma's AI Deployments Will Face FDA Scrutiny by 2027
The FDA issued 40 untitled letters in a single day in September 2025. The next enforcement wave will target AI-driven decisions without audit trails. Here is why your pharma company needs to act now.
May 11 · 3 min read
AI, Pharma
Why Pharma's Best AI Bets Are Boring (And Why That's the Point)
The AI investments that will define pharma's next decade are not the flashy ones. They are the boring ones. Here is what to look for and why your CFO will not approve them.
May 10 · 3 min read
AI, Business, Pharma
How to Brief an AI Agent Like a Senior Partner: A Pharma Operator's Framework
Most pharma teams brief AI agents like search engines. The teams getting results brief them like senior associates. Here is the framework that changes the output.
May 6 · 3 min read
Pharma, AI
Why I Built Human in the Loop for Pharma
Pharma leaders make hundreds of decisions a week with no audit trail. Human in the Loop is the AI deployment model that makes pharma accountable.
Apr 29 · 3 min read
Pharma, AI
AI in Pharma Is an Architecture Decision, Not a Procurement One
Most pharma boardrooms ask which AI model to buy. The companies winning are asking which architecture to build. Here is why that matters.
Apr 8 · 3 min read
Questions
What people ask about AI in pharma.
Want to talk about how this applies to your organization?
30 minute call. No deck. We will figure out if I can help.